![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for the treatment of Metastatic Pancreatic Cancer.
Lead Product(s): ABTL0812,Calcium Folinate,Fluorouracil
Therapeutic Area: Oncology Product Name: ABTL0812
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CTI Life Sciences
Deal Size: $7.6 million Upfront Cash: Undisclosed
Deal Type: Financing March 11, 2024